ARTICLE: Neoadjuvant checkpoint blockade for cancer immunotherapy

AUTHORS: Suzanne L Topalian, Janis M Taube, Drew M Pardoll

JOURNAL: Science. 2020 Jan 31;367(6477):eaax0182. doi: 10.1126/science.aax0182.

Abstract

BACKGROUND: Immunotherapies that target the interaction of programmed death 1 (PD-1) with its ligands, PD-L1 and PD-L2, have ushered in the modern oncology era. The PD-1 pathway is a key mediator of local immunosuppression in the tumor microenvironment (TME) but can also modulate T cell priming against tumor antigens in secondary lymphoid tissues. In advanced inoperable cancers refractory to other treatments, drugs that block the PD-1 receptor on lymphocytes or the PD-L1 ligand on tumor and/or immune cells [anti–PD-(L)1] can mediate tumor regression. Although anti–PD-(L)1 treatment is broadly active and is regarded as a “common denominator” for cancer therapy, many tumors demonstrate de novo or acquired resistance. Using anti–PD-(L)1 therapies in the neoadjuvant (presurgical) setting, when the tumor is potentially “resectable for cure,” presents a potential solution. There is ample oncologic precedent for this approach with presurgical chemotherapies in breast and lung cancer, associating pathologic response with improved long-term clinical outcomes. Our Review focuses on the development of neoadjuvant immunotherapies in the era of PD-1 pathway blockade, highlighting particular considerations for immunological mechanisms, clinical development, and pathologic response assessments.

ADVANCES: The immunologic effects of the PD-1 pathway on T cell priming, effector function, and exhaustion suggest distinct mechanisms underlying neoadjuvant immunotherapy versus chemotherapy. Whereas neoadjuvant chemotherapy can “debulk” tumors preoperatively, neoadjuvant immunotherapy aims to enhance systemic immunity against tumor antigens, eliminating micrometastatic tumor deposits that would otherwise be the source of postsurgical relapse. Furthermore, neoadjuvant PD-(L)1 blockade while the primary tumor is in place, as opposed to adjuvant therapy directed only against micrometastatic disease after resection, leverages higher levels of endogenous tumor antigen present in the primary tumor to enhance T cell priming.

We discuss scientific evidence that supports two different but not mutually exclusive models by which neoadjuvant PD-(L)1 blockade may promote systemic antitumor immunity. First, anti–PD-(L)1 rejuvenates tumor-specific cytotoxic T cells that already reside in the TME, causing their activation, proliferation, and trafficking to micrometastatic deposits. Second, tumor-draining lymph nodes (TDLN) appear to be the focal point for anti–PD-(L)1 activity, where dendritic cell presentation of tumor antigens to T cells is enhanced; these tumor-specific T cells then enter the bloodstream and migrate to tumor sites. The destruction of micrometastases is central to the notion that neoadjuvant PD-1 blockade should result in enhanced relapse-free and overall survival in operable patients who would otherwise relapse after surgery alone.

There is a strong rationale for evaluating neoadjuvant immunotherapy across tumor types. Presurgical drug administration provides abundant on-therapy tissue for in-depth mechanistic and biomarker studies. We discuss data from recent clinical trials of neoadjuvant anti–PD-(L)1 that show that pathologic tumor regression can outpace radiographic regression and demonstrate the involvement of diverse cellular subsets in this process.

OUTLOOK: At present, more than 100 clinical trials of neoadjuvant anti–PD-(L)1 blockade, as monotherapy or combination therapy, are ongoing or planned. Combining anti–PD-1 with anti–CTLA-4 (cytotoxic T lymphocyte–associated protein 4), or with multidrug chemotherapies for triple-negative breast and lung cancer, has yielded substantial pathologic response rates that are encouraging but require longer follow-up. Next-generation trials may help assign patients to postsurgical observation or intervention depending on the degree of pathologic response, similar to the precedent established with nonimmunologic neoadjuvant therapies in breast cancer. Tumors resected after neoadjuvant immunotherapy provide sufficient materials for in-depth scientific interrogations that are expected to further illuminate mechanisms of response and resistance, revealing pathways and molecules that can be cotargeted in new treatment combinations to increase the efficacy of anti–PD-(L)1 therapy.

For the full article, click here.

For a link to the abstract, click here.

Share This Post